SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors

Breast. 2021 Dec:60:58-61. doi: 10.1016/j.breast.2021.08.017. Epub 2021 Aug 28.

Abstract

Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis of immune responses after the first dose of vaccination in 21 breast cancer patients receiving cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The levels of neutralizing antibodies post vaccination were similar to the matched healthy controls, whereas no safety issues have been raised. Further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.

Keywords: Breast cancer; CDK4/6 inhibitors; COVID-19; Vaccination.

MeSH terms

  • Antibodies, Neutralizing* / blood
  • Antibodies, Viral* / blood
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms* / drug therapy
  • COVID-19 Vaccines / immunology*
  • COVID-19* / prevention & control
  • Cyclin-Dependent Kinase 4 / antagonists & inhibitors
  • Cyclin-Dependent Kinase 6 / antagonists & inhibitors
  • Female
  • Humans
  • SARS-CoV-2
  • Vaccination

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antineoplastic Agents
  • COVID-19 Vaccines
  • CDK4 protein, human
  • CDK6 protein, human
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6